This is consistent with the results of Kaufmann et al. [71] who found that protein levels of BCL2, MCL-1, BCL-XL, and BAX, measured at the time of AML or ALL diagnosis, varied over as much as a 40-fold range between individual patients. This evidence concerns the gene BAX and acute lymphoblastic leukemia.